CHIA-HSUIN CHANGLin J.-W.Lai M.-S.2020-10-152020-10-1520110732-183Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-81755171092&doi=10.1200%2fJCO.2011.38.2242&partnerID=40&md5=1a486e92baa78961ace52a84ad71ce80https://scholars.lib.ntu.edu.tw/handle/123456789/517176[SDGs]SDG3angiotensin receptor antagonist; antihypertensive agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; candesartan; dipeptidyl carboxypeptidase inhibitor; hemoglobin A1c; losartan; telmisartan; thiazide diuretic agent; body mass; cancer risk; diabetes mellitus; diabetic nephropathy; diabetic patient; disease duration; Dressler syndrome; drug safety; heart failure; human; letter; priority journalletter10.1200/JCO.2011.38.22422-s2.0-81755171092